15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $14M | -$34M | 0.0% | -271.0% | -$40M | $0 | $18M |
| 2024 | $6M | -$70M | 0.0% | -1236.7% | -$65M | $0 | $36M |
| 2023 | $18M | -$73M | 0.0% | -430.5% | -$87M | $0 | $26M |
| 2022 | $39M | -$69M | 0.0% | -167.8% | -$36M | $0 | $31M |
| 2021 | $11M | -$76M | 0.0% | -669.1% | -$68M | $0 | $109M |
| 2020 | $7M | -$64M | 0.0% | -836.1% | -$52M | — | $52M |
| 2019 | $6M | -$154M | 0.0% | -2394.0% | -$72M | — | $32M |
| 2018 | $6M | -$57M | 0.0% | -1510.2% | -$69M | — | $37M |
| 2017 | $11M | -$84M | 0.0% | -1036.7% | -$56M | — | $54M |
| 2016 | $1M | -$384M | 0.0% | -32973.8% | -$62M | — | $23M |
| 2015 | $23M | -$63M | 0.0% | -446.5% | -$59M | — | $167M |
| 2014 | $15M | -$39M | 0.0% | -223.6% | -$13M | — | $72M |
| 2013 | $15M | -$14M | 0.0% | -78.6% | -$7M | — | $69M |
| 2012 | $14M | $30M | 0.0% | -91.8% | $33M | — | $47M |
| 2011 | $17M | -$10M | 0.0% | -63.6% | -$8M | — | $9M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $179M | $170M | 0.0% | 94.3% | — | $0 | $24M |
| Dec '25 | $1M | -$4M | 0.0% | -503.3% | -$5M | $0 | $18M |
| Sep '25 | $529000 | -$8M | 0.0% | -1636.9% | -$6M | $0 | $22M |
| Jun '25 | $11M | $3M | 0.0% | 13.9% | -$16M | $0 | $37M |
| Mar '25 | $2M | -$25M | 0.0% | -1456.9% | -$13M | $0 | $37M |
| Dec '24 | $2M | -$13M | 0.0% | -885.2% | -$10M | $0 | $36M |
| Sep '24 | $1M | -$20M | 0.0% | -1601.2% | -$21M | $0 | $32M |
| Jun '24 | $2M | -$20M | 0.0% | -1250.5% | -$15M | $0 | $63M |
| Mar '24 | $2M | -$18M | 0.0% | -1263.9% | -$19M | $0 | $43M |
| Dec '23 | $2M | -$19M | 0.0% | -967.2% | -$17M | $0 | $26M |
| Sep '23 | $5M | -$20M | 0.0% | -462.8% | -$22M | $0 | $18M |
| Jun '23 | $5M | -$17M | 0.0% | -395.3% | -$20M | $0 | $27M |
| Mar '23 | $7M | -$16M | 0.0% | -260.4% | -$27M | $0 | $41M |
| Dec '22 | $6M | -$22M | 0.0% | -361.3% | -$17M | $0 | $31M |
| Sep '22 | $6M | -$18M | 0.0% | -299.2% | -$19M | $0 | $24M |
| Jun '22 | $14M | -$14M | 0.0% | -99.1% | -$21M | $0 | $47M |
| Mar '22 | $13M | -$16M | 0.0% | -87.2% | $21M | $0 | $81M |
| Dec '21 | $3M | -$21M | 0.0% | -648.7% | -$20M | $0 | $109M |
| Sep '21 | $3M | -$19M | 0.0% | -551.1% | -$16M | — | $78M |
| Jun '21 | $2M | -$19M | 0.0% | -800.4% | -$15M | — | $31M |
How the market has priced ABUS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Arbutus Biopharma Corp's revenue has grown 15.3% per year. These are computed facts, not advice.
As of FY2025, Arbutus Biopharma Corp reported $0 of total debt against $18M of cash; operating income covered interest expense -393.4×.
In FY2025, gross margin was —, operating margin -271.0%, and net margin -237.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.